The purpose of this study is to evaluate the effectiveness and safety of Pegcetacoplan in patients with C3G and primary IC-MPGN in the real-world setting. This study will also assess biomarkers not routinely measured in clinical practice. Results will support the long-term evaluation of the benefit-risk profile of pegcetacoplan in a broad patient population, informing clinical decision-making.
Inclusion Criteria:
Exclusion Criteria:
medical.info@sobi.com
Calgary, Alberta T3B 6A8, Canada
Vancouver, British Columbia V6H 3V4, Canada
London, Ontario N6A 5W9, Canada
Mainz, 55131, Germany
Villingen-Schwenningen, 78052, Germany
Bari, 70124, Italy
Bologna, 40138, Italy
Bologna, 40138, Italy
Udine, 33100, Italy
Seoul, 6591, South Korea
Seoul, 7061, South Korea
Cambridge, CB2 2QQ, United Kingdom
Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)